The American Academy of Neurology (AAN) recently published their Top Five Recommendations in the Choosing Wisely Campaign in promoting high value neurological care. This was done in collaboration with the American Board of Internal Medicine Foundation and Consumer Reports to reduce ineffective and costly care.
The AAN made clear that the recommendations were intended to promote discussion between patients and their providers about the value of these therapies, not to completely stop the use of specific treatments.
The recommendation to stop prescribing interferon-beta and glatiramer acetate is not unanimously supported by all MS neurologists, many of whom feel that this was an oversimplification.
People with ...